Rehmann Capital Advisory Group’s Intellia Therapeutics NTLA Stock Holding History

Rehmann Capital Advisory Group’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-330	Closed	-$5.4K	–	1978
2019 Q2	$5.4K	Hold	330	–	–	﹤0.01%	1538
2019 Q1	$5.64K	Hold	330	–	–	﹤0.01%	1497
2018 Q4	$4.5K	Sell	330 -14,079	-98%	-$262K	﹤0.01%	1286
2018 Q3	$412K	Buy	+14,409	New	+$419K	0.06%	244

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rehmann Capital Advisory Group's NTLA Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Intellia Therapeutics (NTLA) in Q3 2019, closing a stake of 330 shares — an estimated $5.4K sold.

Rehmann Capital Advisory Group first reported a position in NTLA in Q3 2018 and held it in 4 quarters. The position peaked at $412K in Q3 2018. 136 funds tracked by Wall St. Rank hold NTLA as of Q3 2019.

Rehmann Capital Advisory Group reported no remaining Intellia Therapeutics position as of Q3 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 330 Intellia Therapeutics shares in Q3 2019, an estimated $5.4K.
Rehmann Capital Advisory Group first reported a position in Intellia Therapeutics in Q3 2018 and held it in 4 quarters.
Rehmann Capital Advisory Group's Intellia Therapeutics position peaked at $412K in Q3 2018.
136 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.